Praxis Precision Medicines, Inc. (PRAX) Cash Flow Statement

The OCF/NI ratio has hovered near 0.9 in recent quarters, implying that non-cash charges like stock-based compensation are minimal relative to the overall loss. This indicates that the company's cash burn is a direct reflection of its operational spending, with little cushion from non-cash adjustments. Investors should monitor whether any future divergence emerges as clinical trial costs accelerate.

The quarterly FCF deficit has more than tripled over the observed period, driven by a 157% increase in R&D expenses as late-stage trials ramp up. This trajectory implies that the company is consuming cash at an accelerating pace, which may necessitate dilutive financing before key data readouts. The absence of revenue amplifies the urgency of securing non-dilutive capital or partnerships.

With CapEx consistently under $250K per quarter, the company's capital intensity is minimal, consistent with a clinical-stage biotech that outsources production and trial operations. This suggests that the primary cash outflow is operational R&D spending, not fixed asset investment. The lack of significant capex also implies that future commercialization would require substantial new investment, which is not yet reflected in the cash flow data.

The quarterly working capital adjustments are relatively small compared to the operating loss, suggesting that the company's cash conversion cycle is not a major driver of liquidity. However, the variability may reflect timing of clinical trial invoices and vendor payments, which could cause short-term cash flow volatility. Investors should not over-interpret these swings as they are likely operational noise rather than a structural trend.

The absence of dividends and buybacks underscores that the company is in a pure investment phase, with every dollar of cash allocated to R&D and operations. This capital deployment strategy is consistent with a clinical-stage company that needs to preserve liquidity for binary catalysts. The lack of capital returns also means that shareholder value is entirely dependent on successful pipeline execution.

The small gap between cumulative net income and operating cash flow (about $118M) is largely attributable to non-cash stock-based compensation, which totaled roughly $76M over the period. This implies that the company's reported losses are a reliable proxy for its cash burn, with no significant accrual manipulation. The consistency between earnings and cash flow provides transparency for investors assessing the sustainability of the burn rate.